• NEWS & PUBLICATIONS
  • News and Media
  • Newsletters
  • Journals
  • Books
• MEMBERSHIP
  • Join/Renew
  • Benefits
  • Categories
  • Download a Member Application
  • Grants, Awards, and Scholarships
  • Access the Phantom Analysis Toolkit
  • Membership Directory
  • Chapters
  • Centers of Excellence
  • Councils
  • Member Spotlight
  • Women in Nuclear Medicine
  • SNMMI Fellow
  • SNMMI-TS Fellow
  • Council and Center Internships
• EDUCATION
  • Learning Center
  • 2023 Annual Meeting Call for Abstracts
  • Webinars
• MEETINGS & EVENTS
  • Calendar of Events
  • Webinars
  • 2023 Mid-Winter Meeting
  • 2023 Annual Meeting
  • 2023 Annual Meeting Call for Abstracts
  • Nuclear Medicine & Molecular Imaging Week
  • SNMMI-TS Leadership Academy
  • SNMMI Future Leaders Academy
• ADVOCACY
  • Coding & Reimbursement
  • Legislative Efforts
  • Government Relations News
  • Radiopharmaceutical Supply News
  • USP 825
  • Technologist State Issues
  • Position Statements
  • FDA PET Drug Manufacturing Q&A
• EVIDENCE & QUALITY
  • Clinical Guidelines and AUC
  • Quality
  • Quality and Patient Safety
  • Dose Optimization
  • About Quality & Practice
  • Dosimetry
• RESEARCH
  • Clinical Trials Network
  • Radiopharmaceutical Therapy Central
  • Radiopharmaceutical Therapy Centers of Excellence
  • Preclinical Imaging
  • Nuclear Medicine Clinical Trial Group, LLC
  • Research: Learn More
• ABOUT SNMMI
  • Strategic Plan
  • Bylaws & Procedures
  • Governance - SNMMI
  • Governance - SNMMI-TS
  • History
  • Grants, Awards, and Scholarships
  • Career Center
  • About Nuclear Medicine & Molecular Imaging
  • International Collaboration
  • Outreach
  • Support SNMMI
  • Contact Us

SNMMI News

• PSMA PET Improves Decision Making for Prostate Cancer Treatment

  Mar 24, 2023 — PSMA PET mapping of cancer recurrence in the prostate bed shows that current radiotherapy contouring guidelines—which determine the target areas for treatment—miss a significant number of lesions and may unnecessarily irradiate healthy tissues, according to a new study published ahead of print in JNM. Researchers are calling for redefinition of the guidelines to improve patient outcomes.

• New Compact and Low-Cost Lensless Radiomicroscope Developed for Nuclear Medicine Imaging

  Mar 21, 2023 — A novel, palm-sized imaging modality that can visualize the distribution of medical radiopharmaceuticals with very fine resolution has been developed and successfully tested, according to research published in March JNM. Known as the lensless radiomicroscope, the instrument offers the same level of imaging performance as its closest imaging equivalent but comes with significantly larger field of view and costs less than $100.

• Update, Pluvicto Supply Shortage: How You Can Help

  Mar 20, 2023 — Due to severe production issues, the supply of Pluvicto is not currently sufficient to meet patient need. Please act now!

• Novel PET Radiotracer Successfully Detects Multiple Cancers, Offers Potential for New Targeted Radionuclide Therapy

  Mar 16, 2023 — A new radiotracer, Ga-68 FAP-2286, has been found to be more effective than the most commonly used nuclear medicine cancer imaging radiotracer, F-18 FDG, according to a study published in JNM. Ga-68 FAP-2286 detected 100 percent of primary tumors across multiple cancer types as compared to F-18 FDG, which identified only 80 percent. Ga-68 FAP-2286 was also more effective in detecting lymph node metastases and distant metastases.

• Pluvicto Supply Shortage Update: What SNMMI Is Doing

  Mar 8, 2023 — A supply problem with Pluvicto, the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients, which is having a profound negative impact on patient care.

• SNMMI Applauds Introduction of FIND Act of 2023: Legislation Will Ensure Patient Access to Innovative and Effective Diagnostic Imaging

  Mar 6, 2023 — SNMMI, along with more than 80 stakeholder organizations, supports and applauds the introduction of H.R. 1199, the Facilitating Innovative Nuclear Diagnostic (FIND) Act of 2023. The legislation will ensure patient access to innovative and effective diagnostic imaging.

• SNMMI Mars Shot/Lobular Breast Cancer Alliance Announce Recipient of the Invasive Lobular Carcinoma Imaging Research Fellowship

  Mar 1, 2023 — The SNMMI Mars Shot Research Fund and the Lobular Breast Cancer Alliance (LBCA) are excited to announce that Marina Sharifi, MD, PhD, has been selected as the recipient of the joint SNMMI/LBCA Invasive Lobular Carcinoma Imaging Research Fellowship.

• JNM Publishes Procedure Standard/Practice Guideline for SSTR PET Imaging of Neuroendocrine Tumors

  Feb 21, 2023 — SNMMI and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline to assist physicians in recommending, performing, interpreting, and reporting the results of somatostatin receptor (SSTR) PET imaging for patients with neuroendocrine tumors. The guideline is published in the February issue of The Journal of Nuclear Medicine.

• New Dual-Phase Imaging Protocol Reduces Costs and Radiation Exposure for Cognitively Impaired Patients

  Feb 8, 2023 — A new nuclear medicine imaging protocol can assess both amyloid and neurodegeneration with a single tracer injection, cutting costs and radiation exposure for patients as well as providing them greater comfort. This research was published in the February issue of The Journal of Nuclear Medicine.

• E-Cigarettes Potentially Harmful: PET Imaging Shows Greater Lung Inflammation in E-Cigarette Users Than Cigarette Smokers

  Jan 25, 2023 — PET imaging shows greater lung inflammation in e-cigarette users than in cigarette smokers, according to a new study published ahead of print in JNM.

• Nearly Half of Medicare Patients with Non-Small Cell Lung Cancer Not Staged According to National Guidelines: Lack of Adherence Linked to Greater Mortality Rates

  Jan 17, 2023 — A study published in the January JNM reports that approximately half of Medicare patients with NSCLC do not receive the appropriate imaging prior to radiation therapy. Significant improvement in survival rates was found in patients who had FDG PET/CT imaging—as recommended in NCCN guidelines—compared to those who underwent CT imaging alone.

• Novel PET Radiotracer Reduces Number of False-Positive Cancer Findings After COVID-19 Vaccination

  Jan 10, 2023 — A novel imaging agent, Ga-68 FAPI, can reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for COVID-19, helping prevent costly follow-up and false management decisions for cancer patients.

• FDA Approves New Treatment for Alzheimer's Disease: Presence of Beta Amyloid Must Be Confirmed Before Treatment

  Jan 6, 2023 — A new treatment for Alzheimer’s disease, lecanemab, was approved today by the FDA. Lecanemab has been shown to slow the progression of Alzheimer’s for patients who are in early stages of the disease. Prescribing information instructs physicians to “confirm the presence of amyloid beta pathology prior to initiating treatment.”

• PSMA PET/MRI Accurately Predicts Risk of Prostate Cancer Recurrence

  Jan 5, 2023 — In men recently diagnosed with intermediate or high-grade prostate cancer, PSMA PET/MRI can successfully determine whether their cancer is likely to return within two years of a prostatectomy.

• Nuclear Medicine Bone Scan Study Identifies Prevalence and Outcomes of Cardiac Amyloidosis

  Jan 3, 2023 — Approximately 3% of bone scan patients have markers of cardiac amyloidosis, which can lead to heart failure and increased mortality, according to new research published in JNM. This incidental finding may offer a window of opportunity for treatment.

• Congress passes 2023 Consolidated Appropriations Act

  Dec 29, 2022 — On December 23, 2022, the U.S. House of Representatives passed H.R. 2617, the 2023 Consolidated Appropriations Act (also referred to as the Omnibus package) by a vote of 225-201-1.

• This Month in JNM

  Dec 1, 2022 — In December JNM: A discussion with GU oncologist Declan Murphy … The State of the Art: FAPI PET/CT in nonmalignant diseases … Continuing Education: FDA approval for theranostic agents … Focus on MI: Nanoparticle diagnostics and theranostics … Featured: a-Particle and immunocytokine therapy … Cardiac amyloidosis in bone scan referrals … and more.

• Novel PET Agent Effectively Detects Multiple Cancers, Identifies Patients for Targeted Therapies

  Nov 17, 2022 — A new molecular imaging radiotracer, Ga-68 PentixaFor, can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies.

• SNMMI Announces Ones to Watch 2022 Selections

  Nov 16, 2022 — SNMMI is pleased to present our annual list of 30 early career professionals selected as “Ones to Watch” in 2022!

• 2023 Ones to Watch Nominations

  Nov 16, 2022 — SNMMI is now accepting nominations for our 2023 Ones to Watch selections. We need your help in identifying and recognizing “ones to watch” in the coming years, as they work to shape the future of nuclear medicine and molecular imaging. Members can nominate someone they know—currently in training or who have completed their training within the last 10 years—whose actions, work, or studies have set them apart as a future thought leader in the field.

• PET/MRI Machine Learning Model Can Eliminate Sentinel Lymph Node Biopsy in Majority of Breast Cancer Patients

  Nov 10, 2022 — Nearly 70 percent of breast cancer patients could find out if their cancer has spread to their lymph nodes without having to undergo an invasive sentinel node biopsy, according to new research published in JNM.

• Pomper Wins Minnie’s 2022 Most Influential Radiology Influencer for F-18 DCFPyL

  Oct 27, 2022 — Martin Pomper, MD, PhD, has been named Most Influential Radiology Researcher for 2022 by AuntMinnie for his work in developing F-18 DCFPyL.

• CTN: Enabling Accurate Quantitative PET/CT and SPECT/CT Imaging

  Oct 25, 2022 — Quantitative measurements have long been a strength of nuclear medicine. There is renewed urgency for accurate, reproducible, and standardized measurements in routine clinical practice as the role of diagnostic and therapeutic radiopharmaceuticals in clinical trials and routine clinical care grows. The CTN continues to be involved in this space, with several active projects to address this need.

• Novel PET Imaging Agent Detects Earliest Signs of Alzheimer’s Disease

  Oct 19, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B (MAO-B) in cognitively unimpaired individuals with high beta amyloid, according to research published in the October issue of JNM.

• Ultra-Low Dose Total Body PET/CT Effective for Evaluating Arthritis

  Oct 12, 2022 — Total body PET/CT scans can successfully visualize systemic joint involvement in patients with autoimmune arthritis, according to new first-in-human research published in the October issue of JNM.

• SNMMI and the Lobular Breast Cancer Alliance Announce $100,000 Research Grant

  Oct 3, 2022 — SNMMI announces a new $100,000 grant to fund research on nuclear medicine imaging and treatments for lobular beast cancer. The grant is sponsored by the SNMMI Mars Shot Fund and the Lobular Breast Cancer Alliance.

• New PET Tracer Shows Promise for uPAR-Targeted Therapy of Neuroendocrine Neoplasms

  Sep 28, 2022 — A novel PET radiotracer can accurately assess the presence of a biomarker that indicates the level of tumor aggressiveness in neuroendocrine neoplasms, according to research published in September JNM, and may also serve as a potential target for peptide radionuclide therapy (PRRT) for NEN patients.

• TerraPower Announces Funding Raised for Nuclear Technologies

  Sep 20, 2022 — TerraPower, a nuclear innovation company founded by Bill Gates, announced a $750 million funding raise co-led by Gates and SK, a large South Korean conglomerate that is one of South Korea’s largest energy providers. According to a press release from TerraPower, this effort will enhance the company’s “groundbreaking work in advanced nuclear energy technologies and nuclear medicine.”

• SNMMI PR Campaign Lands Stories in Major Media Markets

  Sep 12, 2022 — SNMMI’s consumer-focused public relations initiative to raise awareness about what nuclear medicine is and what it can accomplish has seen continued success in the summer months.

• A Special Issue of the Journal of Nuclear Medicine Technology Highlights the New Frontier of Theranostics

  Sep 12, 2022 — A special issue of the Journal of Nuclear Medicine Technology focuses on theranostics as it relates to technologists and includes articles on quality and practice management, imaging, and radiation safety, as well as continuing education articles.

• New Research Shows PSMA PET/CT Imaging Changes Management for Close to 50 Percent of Prostate Cancer Patients

  Sep 7, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with 18F-DCFPyL PSMA PET/CT has been shown to considerably improve detection of active disease as compared to imaging with CT alone.

• The DOE Isotope Program Announces its Annual Medical Isotope User Group Meetings

  Aug 14, 2022 — In 2022, the Department of Energy (DOE) Isotope Program will host four virtual medical isotope user group meetings focused on the following emerging alpha and beta emitters: actinium-225, astatine-211, lead-212, and new this year, cerium-134.

• Francoeur to Lead Patient Advocacy Advisory Board for Society of Nuclear Medicine and Molecular Imaging

  Aug 11, 2022 — Jeri Francoeur of Ormond Beach, Florida, has been elected to a two-year term as chair of SNMMI's Patient Advocacy Advisory Board.

• Crosby Elected Vice Chair of Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging

  Aug 11, 2022 — Mike Crosby of San Diego, California, has been elected to a two-year term as vice chair of SNMMI's Patient Advocacy Advisory Board.

• SNMMI Urges Congress to Avert Cuts to Physician Reimbursement

  Aug 4, 2022 — Recently SNMMI—with more than 100 medical societies and various industry groups—espoused its support in two letters for averting cuts to the Medicare Physician Fee Schedule (MPFS) Proposed Rule.

• The Journal of Nuclear Medicine Sheds Light on the Challenges of Medical Practice in Wartime Ukraine

  Aug 1, 2022 — The Journal of Nuclear Medicine has published a first-hand account of the daily practice of nuclear medicine and molecular imaging during the ongoing war in Ukraine.

• CMS releases its CY 2023 Medicare Physician Fee Schedule Proposed Rule

  Jul 14, 2022 — The Centers for Medicare and Medicaid Services (CMS) released its 2023 Medicare Physician Fee Schedule (MPFS) Proposed Rule on July 7.

• Safe and Equitable Healthcare for All: SNMMI’s Position on the Doctor-Patient Relationship

  Jul 8, 2022 — SNMMI statement: Safe and Equitable Healthcare for all: SNMMI’s position on the Doctor-Patient Relationship

• In the July Issue of The Journal of Nuclear Medicine

  Jul 6, 2022 — Editorial—Unacceptable denials of PSMA-Targeted PET/CT imaging … COVID-19 and the brain … Standard of care—Alzheimer disease … Radiotracers in cardiovascular imaging … Women authors in nuclear medicine journals … Featured: C-11-PiB PET in AL cardiac amyloidosis … Pretargeting and trastuzumab combination … and more.

• Journal of Nuclear Medicine Impact Factor Rises Again

  Jun 29, 2022 — The Journal of Nuclear Medicine has again achieved the highest impact factor in its history, ranking fourth among all medical imaging journals worldwide, according to new data just released in Clarivate's 2021 Journal Citation Reports.

• Aetna Reverses Cardiac PET/CT Non-Coverage & Updates Policy for PSMA Therapy

  Jun 27, 2022 — SNMMI and ASNC requested that Aetna reverse its non-coverage cardiac PET/CT policy. We are thrilled to communicate that within a few days of receiving our letter, Aetna reversed the policy. Also, Aetna recently updated and published their coverage policy for PSMA imaging for PLUVICTO therapy eligibility.

• CMS Reopens NCD for Beta Amyloid PET in Dementia and Neurodegenerative Disease

  Jun 24, 2022 — On June 16, 2022, the Centers for Medicare and Medicaid Services (CMS) began a reconsideration process for its National Coverage Determination (NCD) for Beta Amyloid Positron Emission Tomography (PET) in Dementia and Neurodegenerative Disease

• Nuclear Medicine and Molecular Imaging Community Gathers at SNMMI 2022 Annual Meeting

  Jun 16, 2022 — SNMMI hosted more than 6,700 physicians, technologists, pharmacists, laboratory professionals, scientists and others at its 2022 Annual Meeting last week in Vancouver, British Columbia, Canada.

• Novel Radiopharmaceutical Pair Detects and Treats Melanoma; Study Shows Potential for Broad Application in Solid Tumors

  Jun 14, 2022 — A newly developed small-molecular radiopharmaceutical pair has successfully visualized and treated melanoma in a preclinical study, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• PSMA PET Highlights Need for Updated Prostate Cancer Therapy Guidelines

  Jun 14, 2022 — Current guidelines used to plan salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to take into consideration information derived from novel imaging modalities, such as PSMA PET.

• Revolutionary Technology Shortens Cardiac Scan Time, Provides High-Quality SPECT Images

  Jun 14, 2022 — A cardiac SPECT imaging system performs scans 10 to 100 times faster than current SPECT systems, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• SNNMI Abstract of the Year: Targeted Radionuclide Treatment Achieves High Response Rate, Minimal Toxicities for Advanced-Stage Neuroendocrine Tumors

  Jun 14, 2022 — A targeted radionuclide alpha therapy, Ac-225 DOTATATE, has been shown to have long-term anti-tumor effects in patients with advanced-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

• SNMMI Image of the Year: New Biomarker Predicts Severity of Cardiac Remodeling after Heart Attack

  Jun 14, 2022 — Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, Ga-68-FAPI-46. The detailed depiction of Ga-68-FAPI-46 PET signal after acute anterior myocardial infarction has been selected as SNMMI’s 2022 Image of the Year.

• SNMMI Elects Cathy Sue Cutler, PhD, FSNMMI, as Vice President-Elect at 2022 Annual Meeting

  Jun 13, 2022 — Cathy Sue Cutler, PhD, FSNMMI, director of the medical isotope research and production program at Brookhaven National Laboratory in Upton, New York, has been named as vice president-elect for the Society of Nuclear Medicine and Molecular Imaging.

• SNMMI Announces Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, as President of the Technologist Section During 2022 Annual Meeting

  Jun 13, 2022 — Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, instructor and clinical coordinator at the University of Alabama at Birmingham in Birmingham, Alabama, has been elected as the 2022-23 president for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS).

• SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as President at 2022 Annual Meeting

  Jun 13, 2022 — Munir Ghesani, MD, FACNM, FACR, chief of nuclear medicine and molecular imaging at Mount Sinai Health System and associate professor of radiology at Mount Sinai Hospital in New York, NY, has been named as president for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

• SNMMI Launches Mars Shot Fund for Nuclear Medicine Research; Initial Donations Top $600,000

  Jun 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) today announced the creation of the Mars Shot Fund, an initiative to raise $100 million to help pay for research into nuclear medicine, molecular imaging, and therapy.

• SNMMI Announces Dmitry Beyder, CNMT, MPA, as President-Elect of the Technologist Section During 2022 Annual Meeting

  Jun 13, 2022 — Dmitry Beyder, CNMT, MPA, radiology program manager of nuclear medicine, PET, CT and patient transport at Barnes-Jewish Hospital/Mallinckrodt Institute of Radiology in St. Louis, Missouri, has been elected as the 2022-23 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS).

• Simon R. Cherry, PhD, Receives 2022 Benedict Cassen Prize for Research in Molecular Imaging

  Jun 13, 2022 — Simon R. Cherry, PhD, known for his pioneering work in the development of PET technology and co-development of the EXPLORER total-body PET/CT scanner, was awarded the Benedict Cassen Prize during the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• Andrei Iagaru, MD, FACNM, Receives Inaugural SNMMI Sam Gambhir Trailblazer Award

  Jun 13, 2022 — Andrei Iagaru, MD, FACNM, professor of radiology (nuclear medicine) and chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University, in Stanford, California, has been named as the first recipient of the Sam Gambhir Trailblazer Award.

• Society of Nuclear Medicine and Molecular Imaging Announces 2022 Fellows

  Jun 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging recognized 15 new SNMMI Fellows on Monday, June 13, during a plenary session at the society’s 2022 Annual Meeting.

• Virtual CT Scans Cut Patient Radiation Exposure in Half During PET/CT Studies

  Jun 12, 2022 — A novel artificial intelligence method can be used to generate high-quality “PET/CT” images and subsequently decrease radiation exposure to the patient.

• Molecular Imaging Biomarker Predicts Response to CAR T Cell Therapy

  Jun 12, 2022 — A new PET imaging agent, F-18 AlF-FAPI-74, has been found to effectively monitor and predict treatment response of CAR T cell therapy. This non-invasive imaging approach has the potential to help inform important clinical decision-making early in the course of treatment—including re-dosing of therapy, dose optimization, change of therapeutic course, and many more—to optimize patient outcomes.

• Robert H. Mach, Phd, Receives SNMMI 2022 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jun 12, 2022 — Robert H. Mach, PhD, has been named the 2022 recipient of the prestigious Paul C. Aebersold Award.

• Markus Schwaiger, MD, Receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award

  Jun 12, 2022 — Markus Schwaiger, MD, a scientist known for his contributions to cardiac PET imaging, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

• PET Imaging Confirms Link Between Obstructive Sleep Apnea and Heart Blood Flow Impairment

  Jun 11, 2022 — Patients with severe obstructive sleep apnea (OSA) are less able to increase blood flow to the heart when needed, according to a first-of-its-kind PET imaging study presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• Novel PET Agent Highly Effective for Imaging Meningiomas; Offers Logistical Advantages Over Standard Agents

  Jun 11, 2022 — A novel somatostatin-receptor (SSTR) targeting peptide—18F-SiTATE—has been shown to provide excellent imaging in patients with meningiomas, identifying bone involvement and lesions previously undetected on standard morphological imaging.

• Novel Ultra-Low Dose PET Technique Significantly Reduces Radiation Exposure

  Jun 11, 2022 — A new PET imaging technique can greatly reduce the amount of patient radiation exposure by eliminating the need for an accompanying CT scan. Without the CT scan, the amount of radiation delivered to the patient is cut dramatically, which benefits all patients, but in particular the pediatric population and those in need of multiple scans.

• New Targeted Radionuclide Alpha Therapy Improves Prostate Cancer Outcomes

  Jun 11, 2022 — A novel targeted radionuclide alpha therapy for metastatic castration-resistant prostate cancer—225AC-NM600—has been shown to achieve significantly better outcomes than its corresponding targeted radionuclide beta therapy.

• PET/CT Effective in Evaluating and Monitoring Post-COVID-19 Lung Disease

  Jun 11, 2022 — F-18 FDG PET/CT has been proven successful in evaluating lung inflammation and monitoring treatment effects in patients suffering from post-COVID-19 lung disease.

• JNM Supplement Explores Opportunities for Molecular Imaging of Neurodegeneration

  Jun 2, 2022 — In response to the ongoing paradigm shift in how neurodegenerative diseases are defined and diagnosed—as well as the new hope for a breakthrough in disease-modifying drugs—The Journal of Nuclear Medicine has issued a supplement on molecular imaging of neurodegeneration.

• In the June Issue of The Journal of Nuclear Medicine

  Jun 1, 2022 — In the June issue of JNM: A Letter from Ukraine … Discussion with Peter J. O’Dwyer: Precision medicine in cooperative trials … Issues and Controversies: The VISION Forward … The State of the Art: Guidelines for theranostics … Continuing Education: Lu-177-PSMA and prostate cancer … Hot Topics: Tau, amyloid, and atrophy … Featured: PET and DLBCL response … Radiotherapy ligands for FAP … and more.

• SNMMI & Partners Urge Congress to Support Increased Federal Research Funding

  May 16, 2022 — SNMMI and 368 members of the Ad Hoc Group for Medical Research sent a letter to Congress requesting that the Labor-HHS Subcommittee be allocated sufficient funding to allow for investment in NIH and other agencies that promote the health of our nation. The letter also urged Congress to work expeditiously to complete FY 2023 appropriations in a timely manner.

• Iohexol (Omnipaque) and Iodixanol (Visipaque) Shortage

  May 12, 2022 — A shortage of iohexol (Omnipaque) is occurring as a result of the Chinese government lockdowns related to COVID-19. The alternative agent, iodixanol (Visipaque), is in short supply due to an increase in demand.

• Novartis Announces Temporary Halt in Production of Lutathera and Pluvicto

  May 5, 2022 — On May 5, Novartis announced that it will temporarily suspend production of Lutathera and Pluvicto at its radioligand therapy production sites in Ivrea, Italy, and Milburn, New Jersey, affecting both commercial and clinical trial supply.

• Active Brown Adipose Tissue Protects Against “Pre-Prediabetes”

  May 4, 2022 — In a prospective study of young, lean adults, PET/CT imaging revealed that higher levels of active brown adipose tissue (also known as “brown fat”) are more prevalent in individuals who exhibit very early indications of metabolic disorders. The research was published ahead of print in The Journal of Nuclear Medicine.

• JNM Publishes Joint Guide for the Establishment of Theranostics Centers

  Apr 29, 2022 — SNMMI, the European Association of Nuclear Medicine, and the International Atomic Energy Agency have created a new guide for the creation of dedicated theranostics centers.

• SNMMI and Partners Request a Hearing for the FIND Act

  Apr 28, 2022 — This week, SNMMI and over 70 organizations sent a letter to House Energy and Commerce and Ways and Means Committee Leadership requesting a hearing on the Facilitating Innovative Nuclear Diagnostics (FIND) Act.

• Novel Deep Learning Method Provides Early and Accurate Differential Diagnosis for Parkinsonian Diseases

  Apr 21, 2022 — A new deep learning method has been created to aid in the diagnosis of parkinsonian diseases, according to research published in JNM.

• New ASNC/SNMMI Training Course Helps Physicians Meet U.S. Requirements for Handling Medical Radioisotopes

  Apr 12, 2022 — SNMMI and ASNC have released a new “80 Hour Radionuclide Authorized User Training Course” for nuclear medicine physicians, which will fulfill the 80 hours of classroom training required by the NRC and Agreement States for physicians to become Authorized Users.

• DOE Announces $1 million in Funding for Radioisotope Research

  Apr 11, 2022 — On April 11, the U.S. Department of Energy (DOE) announced $1 million in funding for isotope development.

• SNMMI Releases Statement on CMS Final Decision for Alzheimer’s Disease Coverage

  Apr 8, 2022 — CMS has announced its final decision on coverage of monoclonal antibodies to treat Alzheimer’s disease. It includes no additional coverage for beta amyloid PET scans, which will continue to be limited to one per patient per lifetime.

• New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients

  Apr 7, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre-treated metastatic castration-resistant prostate cancer. The research was published in the April issue of JNM.

• In the April Issue of The Journal of Nuclear Medicine

  Mar 31, 2022 — In April JNM: Thomas Hope talks with Josh Mailman … State of the Art: AI algorithm development best practices … Hot Topics: Virtual biopsy … CE: Kinetic analysis … Special Contribution: PET/MRI scanner trial qualification … FEATURED: Lu-177-PSMA-617 and NOX66 in mCRPC … Blind restoration digital autoradiogram … and more.

• SNMMI Hosts AI and Patient Access Summits

  Mar 28, 2022 — On March 21-23, SNMMI hosted two summits in Bethesda, MD, on Artificial Intelligence and Barriers to Patient Access. The aim of the summits—the first of their kind for the society—was to bring together thought leaders to discuss current obstacles in the field of nuclear medicine and provide solutions. Read the highlights.

• SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

  Mar 23, 2022 — SNMMI applauds the FDA's approval of a new, game-changing nuclear medicine treatment for metastatic prostate cancer shown to reduce risk of death by 38% and risk of progression by 60% in mCRPC patients.

• Molecular Imaging Uncovers Effects of COVID-19 on the Brain

  Mar 15, 2022 — A significant number of COVID-19 neurological complications—such as fatigue, headache, and cognitive impairment—are ultimately reversible, according to new research in The Journal of Nuclear Medicine.

• New Issue of Clinical Trials Newsletter "Pathways" Now Available

  Mar 11, 2022 — The February 2022 issue of the SNMMI Clinical Trials Network newsletter, Pathways, is now available online.

• SNMMI Designates First Radiopharmaceutical Therapy Centers of Excellence

  Mar 10, 2022 — SNMMI has named Stanford Health Care and the Dana-Farber Brigham Cancer Center as its first two designated Radiopharmaceutical Therapy Centers of Excellence.

• Novel Radioligand Therapy Proven Superior for Metastatic Prostate Cancer Patients

  Mar 9, 2022 — A novel prostate cancer treatment—Ac-225 PSMA-617 radioligand therapy—has been shown to increase the progression free survival and overall survival of metastatic castration-resistant prostate cancer patients, according to research published by JNM.

• SNMMI Supports ARPA-H Act

  Mar 4, 2022 — SNMMI signed on as a supporting organization to the Advanced Research Project Agency Health (ARPA-H) Act and offered to be a resource as the bill's sponsor continues to refine the legislative text.

• This Month in JNM

  Mar 3, 2022 — In March JNM: Discussion with Dominique Le Guludec … State of the Art: History of PSMA theranostics … Hot Topics: Oligometastatic prostate cancer therapy … CE: Methodology of kinetic analysis … Focus on MI: Multimodality imaging of aortic stenosis … Featured: Lu-177 FAP-2286 PTRT for adenocarcinoma … CSF-1R inhibition in stroke … and more.

• SNMMI Statement on Aggression in Ukraine

  Mar 1, 2022 — SNMMI deplores the recent invasion of Ukraine that has resulted in the death and injury of a large number of innocent men, women, and children—a horrifying contrast to our work to save lives and improve patient care.

• SNMMI COVID-19 Task Force Vaccination Recommendation

  Feb 28, 2022 — The SNMMI COVID-19 Task Force strongly urges all eligible SNMMI members and healthcare professionals to be vaccinated and receive a booster as soon as possible.

• Medical Isotope Supply—Continuing Progress with HFR

  Feb 23, 2022 — HFR reactor operator NRG has submitted a repair plan to the Dutch regulatory authorities and expects to restart on March 17.

• SNMMI Congratulates FDA Commissioner Califf

  Feb 18, 2022 — SNMMI congratulates Robert Califf, MD, on his confirmation as the 25th Commissioner of the U.S. Food and Drug Administration.

• SNMMI Advocates for Expanded Coverage & Reimbursement of Amyloid PET

  Feb 17, 2022 — When CMS issued a national coverage determination analysis for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease, SNMMI took action.

• HFR Reactor Outage – Medical Isotope Supply Returning to Normal

  Feb 15, 2022 — The isotope supply is returning to normal. NRG plans to restart the HFR reactor March 17; the MARIA research reactor has added operating days; the BR2 reactor resumed operations 3 days early; IRE will resume HEU production later this week.

• NRC Votes to Establish Requirements for Rubidium-82 Generators and Emerging Medical Technologies

  Feb 7, 2022 — Along with voting on training and experience requirements for authorized users, the Nuclear Regulatory Commission (NRC) approved of initiating rulemaking to modernize 10 Code of Federal Regulations (CFR) Part 35.

• NRC Votes on Training and Experience Requirements

  Feb 4, 2022 — The Nuclear Regulatory Commission (NRC) recently voted on training and experience requirements (T&E) for Authorized Users (AUs), disapproving of their staff’s recommendations. SNMMI strongly supports this long-awaited decision.

• This Month in JNM

  Feb 1, 2022 — A discussion with Silke Gillessen … State of the Art: ComBat harmonization guide … Hot Topics: Evaluating LATE … Focus on MI: T-cell PET imaging toolbox … Standard of Care: Differentiated thyroid cancer … Featured: Ga-68 NODAGA-exendin-4 PET/CT in focal CHI … At-211 labeled therapy for prostate cancer … and more.

• SNMMI Launches New Quality Systems Personnel Training Program

  Jan 31, 2022 — SNMMI has launched the Quality Systems Personnel Training Program (QSPTP) to educate, train, and develop individuals with a pharmacy or chemistry background in the production and release of clinical radiopharmaceuticals.

• Alert: HFR Outage Will Impact Isotope Supply

  Jan 26, 2022 — On January 24, Nuclear Medicine Europe communicated that there will be a delay in the restart of the HFR Reactor that will impact the supply of Mo-99 and Lu-177 in coming weeks.

• PSMA PET Validates EAU Classification System to Determine Risk of Prostate Cancer Recurrence

  Jan 20, 2022 — Research published in the January issue of JNM has confirmed the accuracy of the European Association of Urology risk classification system that groups prostate cancer patients based on their risk of recurrence.

• SNMMI Statement: Possible Effect of Omicron Infection on FDG PET/CT Scans

  Jan 14, 2022 — SNMMI's COVID-19 Task Force makes new recommendations for FDG PET/CT and FDG PET/MR in relation to the Omicron variant.

• SNMMI Reacts to CMS Coverage Decision on New Alzheimer’s Therapy

  Jan 12, 2022 — On January 11, CMS announced that it proposes to cover FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease under CED in CMS-approved randomized controlled trials. SNMMI reacts.

• PET/CT Artificial Intelligence Model Ideal for Predicting Risk of Future Heart Attack

  Jan 11, 2022 — When assessed together in an AI model, coronary F-18 NaF uptake on PET and quantitative coronary plaque characteristics on CT angiography were found to provide risk prediction superior to that of clinical data alone.

• JNM Publishes Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

  Jan 7, 2022 — SNMMI and peer medical groups have issued AUC for PSMA PET imaging. Published in the January issue of JNM, the criteria are the product of an international multidisciplinary panel of expert healthcare providers.

• This Month in JNM

  Jan 4, 2022 — Discussions with Leaders – Nuclear medicine in Australia … State of the Art – a-emitter labeling review … Hot Topics – Imaging ICI-induced myocarditis … Focus on MI – Molecular breast imaging … SNMMI appropriate use criteria for PSMA PET imaging … Featured: 68Ga-FAPI PET/CT in fILD and LC … 18F-FAraG imaging of CNS T cells … and more.

• SNMMI Supports Intent of No Surprises Act, Issues Further Recommendations

  Dec 23, 2021 — SNMMI strongly supports the goals of the No Surprises Act—including protecting patients from surprise medical bills, improving the availability of affordable, high-quality, in-network care, and developing a fair and impartial process for resolving provider-insurer payment disputes—and recommends that the government make specific clarifications to the interim final rules.

• FDA Approves New PSMA Kit, Increasing Access to Ga-68 Prostate Cancer Imaging

  Dec 21, 2021 — On December 20, the FDA approved a new kit for preparation of gallium-68 PSMA-11 injection for PET imaging of PSMA-positive lesions in men with prostate cancer, making Ga-68 PSMA-11 PET imaging more widely available in the U.S.

• A Call to Action to Ensure Federal Funding for Scientific Research

  Dec 14, 2021 — SNMMI and the Academy of Radiology and Biomedical Imaging Research have partnered to urge Congress to pass an FY22 appropriations package that supports the National Institutes of Health (NIH) and biomedical imaging, while stopping the use of harmful continuing resolutions (CRs).

• Senate Passes Protecting Medicare and American Farmers from Sequester Cuts Act

  Dec 10, 2021 — Last night, SNMMI and more than 300 medical societies rejoiced when the Senate passed the Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610).

• JNM Supplement Addresses Radiopharmaceutical Dosimetry for Cancer Therapy

  Dec 6, 2021 — Can the tailoring of drug dosage improve the effectiveness of radiopharmaceutical therapy (RPT) for cancer patients? JNM has issued a new supplement addressing both the rapid progress and the challenges in applying patient-specific radiation dosimetry to guide RPT.

• With a New Bill, SNMMI Urges Congress to Avert Cuts to Physician Reimbursement

  Dec 1, 2021 — Once again, SNMMI and more than 300 medical societies voiced their support for averting the looming cuts to the Medicare Physician Fee Schedule (MPFS). Following the release of the Calendar Year 2022 MPFS Rule that indicated the Centers for Medicare and Medicaid Services (CMS) will allow this payment adjustment to expire at the end of 2021, Reps. Bera, MD and Bucshon, MD introduced H.R. 6020. Their bipartisan legislation would extend the 3.75% update to the conversion factor for an additional year.

• This Month in JNM

  Dec 1, 2021 — In December JNM: Discussion with leaders—Mark Mintun, MD … State of the Art—Combination PSMA theranostics … Hot Topics—Embolization of liver-dominant NETs … Focus on MI—21st century imaging biomarkers … Featured—Dual-phase 18F-FPCIT PET in PD … Modifying 223Ra distribution … and more.

• CMS Grants Transitional Pass-Through Payment Status for PSMA PET Imaging Agent for Prostate Cancer

  Nov 24, 2021 — On November 22, CMS granted transitional pass-through payment status for 18F-piflufolastat, increasing patient access to an innovative imaging approach for detecting the spread of prostate cancer to other parts of the body.

• Novel Radionuclide Therapy Proven Safe and Effective to Treat Neuroendocrine Neoplasms

  Nov 19, 2021 — A new type of PRRT has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some patients, according to research published in JNM.

• SNMMI Lauds CMS Decision to Expand Coverage for Non-Oncologic PET

  Nov 11, 2021 — SNMMI lauds last week’s decision by CMS to remove exclusionary language relating to the non-oncologic use of PET, expanding access to critical care for patients.

• CMS Publishes MPFS and OPPS Final Rules Expanding Coverage for Non-Oncologic PET

  Nov 9, 2021 — Last week, the Centers for Medicare and Medicaid Services (CMS) finalized its Medicare Physician Fee Schedule (MPFS) and Hospital Outpatient Prospective System (OPPS) rules.

• This Month in JNM

  Nov 2, 2021 — In November JNM: The need to assess PSMA expression prior to PSMA-targeted radioligand therapy … A discussion with Andrew M. Scott … Production and supply of a-emitters … Gut–brain axis imaging in PD … Featured: Neoadjuvant PRRT with 177Lu-DOTATATE … LAG-3 imaging and therapy response … SNMMI/ASNC practical guide to cardiac PET measurements of MBF … and more.

• Molecular Imaging Suggests Long-COVID Symptoms May Be Caused by Fatigue, Not Regional Brain Dysfunction

  Oct 29, 2021 — Long-term cognitive problems after a COVID-19 diagnosis may be a result of fatigue rather than pathological changes in the brain, according to a study published ahead-of-print in JNM.

• SNMMI 2021-2023 Wagner-Torizuka Fellowship Recipient Announced

  Oct 15, 2021 — SNMMI is pleased to announce the recipient of the 2021-2023 SNMMI Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 by the late Henry N. Wagner, Jr., MD, and the late Kanji Torizuka, MD, PhD, is designed to provide extensive training and experience in the fields of nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers. Applications are available for 2022-2024 fellowships.

• Now Available! PET/CT in Oncology 2021: Part 1

  Oct 7, 2021 — The SNMMI-TS has just released a new book in the SNMMI-TS Quality and Safety Series: PET/CT in Oncology 2021: Part 1. Members can now access the PDF version and interactive online edition free of charge, or receive a 50% discount on the printed book available in the SNMMI Store.

• PSMA PET Imaging More Accurate Than CT in Detecting Hepatocellular Carcinoma

  Sep 30, 2021 — PSMA PET/CT is more accurate than conventional CT in the detection of hepatocellular carcinoma metastases and was associated with a change of management for nearly half of patients, according to research published in the September issue of The Journal of Nuclear Medicine.

• Introducing the SNMMI Annual Awards Guide

  Sep 30, 2021 — The SNMMI is excited to publish its first comprehensive awards publication, SNMMI Annual Grants & Awards Recognition, highlighting the recipients of the many honors, awards, grants, and scholarships presented by the SNMMI and SNMMI-TS in the past year.

• Newly Approved PET Imaging Agent Solves Clinical Dilemmas in Breast Cancer Patients

  Sep 29, 2021 — A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise, according to research published in the September issue of The Journal of Nuclear Medicine.

• New Radionuclide Therapy Identified for HER2-Positive Breast Cancer Patients

  Sep 28, 2021 — A promising radionuclide treatment may offer new therapeutic options for breast cancer patients, according to research published in The Journal of Nuclear Medicine.

• Patients Spotlight Nuclear Medicine in Prominent Magazine/Website

  Sep 27, 2021 — Interviews of patient advocates Josh Mailman and Theresa Wickerham were featured recently in Authority Magazine and the website ThriveGlobal. The stories outline how they are surviving cancer with help from nuclear medicine diagnostics, therapies and theranostics.

• The FIND Act Gets a Senate Companion Bill

  Sep 26, 2021 — On August 4, 2021, Senators Marsha Blackburn (R-TN) and Tammy Baldwin (D-WI) introduced the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 (S. 2609), legislation that would significantly expand patient access to advanced nuclear diagnostic imaging technologies.

• SNMMI, Medical Groups Issue Appropriate Use Criteria for PSMA PET Imaging

  Sep 22, 2021 — A new set of appropriate use criteria is now available to guide referring and imaging physicians in their use of prostate-specific membrane antigen (PSMA) PET imaging agents to detect prostate cancer.

• SNMMI Statement: COVID-19 and Ventilation/Perfusion (V/Q) Lung Studies

  Sep 22, 2021 — SNMMI has updated its statement on V/Q lung studies V/Q lung scans.

• SNMMI Shares Latest Advances in Nuclear Medicine with Patient Audience

  Sep 17, 2021 — SNMMI’s 10th Annual Patient Education Day drew more than 220 patients, caregivers, and advocates, providing insights into the role of nuclear medicine and molecular imaging in disease diagnosis, staging, and treatment.

• ACMUI Backs SNMMI's Recommendations on Extravasation Reporting

  Sep 3, 2021 — Yesterday, the ACMUI Subcommittee on Extravasations reviewed and provided further recommendations on the NRC Staff Preliminary Evaluation of Radiopharmaceutical Extravasation and Medical Event Reporting in a public meeting. In anticipation of the meeting, SNMMI provided public comment.

• This Month in JNM

  Sep 2, 2021 — In September JNM: Editor’s Page: JNM impact factor reaches a new milestone … Discussions with leaders: Caius Radu … State of the Art: Image-Guided HIFU in nuclear medicine … Hot Topics: Cardiac PET and the future … Continuing Education: Pheochromocytoma and paraganglioma … Focus on MI: Current clinical pretargeting … Issues and Controversies: Diversity in nuclear medicine. Featured: Pretargeted immuno-PET in MTC … 68Ga-BMS-986192 for PD-L1 PET … and more.

• California Members: Act Now to Oppose A.B 1273

  Aug 12, 2021 — Earlier this year, Assemblyman Freddie Rodriguez introduced A.B 1273, Interagency Advisory Committee on Apprenticeship: the Director of Consumer Affairs and the State Public Health Officer. Our SNMMI-TS Advocacy Committee acted quickly and submitted an opposition letter prior to the public hearing before the Senate Health Committee. This harmful piece of legislation is now up for a (Senate) floor vote, so we are calling our members to act quickly to oppose it.

• SNMMI Participates in "ACGME Equity Matters" Initiative

  Aug 4, 2021 — SNMMI is proud to announce its partnership in ACGME Equity Matters, a new initiative that introduces a framework for continuous learning and process improvement in the areas of diversity, equity, and inclusion (DEI) and anti-racism practices.

• CMS Revokes Coding Barriers for 18F FDG PET Infection and Inflammation NCD Retirement

  Aug 3, 2021 — In December 2020, CMS retired the National Coverage Determination for F-18 FDG PET for infection and inflammation, effective January 1, 2021. On June 8, CMS put forth certain ICD-10 codes for osteomyelitis and fever of unknown origin in a transmittal—which they would NOT cover. Yesterday, that decision was reversed.

• This Month in JNM

  Aug 2, 2021 — In August JNM: Perspectives on Cutting-Edge Clinical Trials … Hot Topics: Targeted radionuclide therapy trials … Editorial: 18F-FDG for inflammation and infection … Featured articles: 18F-Enzalutamide for androgen expression … 18F-Fluciclovine and radiotherapy decisions … and more.

• Topical Molecular Imaging Tracer Enables Real-Time Detection of Cervical Cancer

  Jul 27, 2021 — With the help of a topical fluorescent imaging agent, cervical cancer can be identified by physicians with a hand-held microscope, according to research published in the July issue of JNM.

• SNMMI Comments on CURES 2.0 Proposal

  Jul 26, 2021 — When Reps. Upton and DeGette requested comment on their 21st Century Cures 2.0 proposal, we listened. The bill aims to continue the acceleration of the discovery, development, and delivery of 21st century cures. The coalition's letter urged Congress to use this opportunity to expand Medicare beneficiary access to diagnostic radiopharmaceuticals.

• Novel Imaging Agent Identifies Biomarker for Iron-Targeted Cancer Therapies

  Jul 22, 2021 — A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients.

• SNMMI and Coalition Partners Applaud the Introduction of the FIND Act

  Jul 21, 2021 — On July 16, Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC) introduced the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 (H.R. 4479), legislation that would significantly expand patient access to advanced nuclear diagnostic imaging technologies.

• CMS Announcements Hold Big Surprises for PET Scans

  Jul 19, 2021 — Last week brought two big announcements from CMS: a national coverage analysis notice on Alzheimer's disease treatment and the Medicare Physician Fee Schedule (MPFS).

• SNMMI Announces Ones to Watch 2021 Selections

  Jul 16, 2021 — SNMMI is pleased to present our annual list of 30 early career professionals selected as “Ones to Watch” in 2021!

• The Journal of Nuclear Medicine Spotlights the Future of Nuclear Endocrinology

  Jul 15, 2021 — A new JNM supplement focuses on nuclear endocrinology, including novel approaches and updates on imaging for hyperparathyroidism, thyroid nodules, thyrotoxicosis, adrenal masses, brown adipose tissue, hyperinsulinism, pituitary adenomas, and more.

• This Month in JNM

  Jul 13, 2021 — In July JNM—Discussion with Leaders: Lou Marzella … Hot Topics: Pharmacogenomics in radionuclide therapy … CE: Nuclear medicine in benign thyroid disease … Focus on MI: Immunometabolism and atherosclerosis ... COVID Commentary: Cognitive recovery in chronic COVID-19 … Featured: PSMA RLT proteomics/phosphoproteomics … Anti-PD-1 response in NSCLC … and more.

• Total-Body PET Imaging Exceeds Industry Standards

  Jul 7, 2021 — A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high sensitivity that supports excellent spatial resolution and image quality, according to research published in The Journal of Nuclear Medicine.

• Molecular Imaging Improves Staging and Treatment of Pancreatic Ductal Adenocarcinomas

  Jul 5, 2021 — For patients with pancreatic ductal adenocarcinomas, molecular imaging can improve staging and clinical management of the disease, according to research published in JNM.

• Journal of Nuclear Medicine Impact Factor Surges More than 27%

  Jul 1, 2021 — The Journal of Nuclear Medicine has again achieved the highest impact factor ever in its history, now ranking third among all medical imaging journals worldwide, according to new data just released in the 2020 Journal Citation Reports.

• SNMMI Submits Senate Testimony Supporting Additional NIH Funding

  Jun 24, 2021 — Yesterday, SNMMI filed its Outside Witness Testimony in support of increased funding for the National Institutes of Health. In it, the Society continues to promote at least $46.1 billion for NIH.

• PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

  Jun 15, 2021 — A phase III clinical trial has validated the effectiveness of the PSMA-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer. This study was presented at the SNMMI 2021 Annual Meeting.

• SNMMI Announces Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, as President-Elect of the Technologist Section During 2021 Annual Meeting

  Jun 15, 2021 — Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, has been elected as the 2021-22 president-elect for the SNMMI-TS.

• SNMMI Announces Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT) as President of the Technologist Section During 2021 Annual Meeting

  Jun 15, 2021 — Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT), has been elected as the 2021-22 president for the SNMMI-TS.

• SNMMI Image of the Year: PET Imaging Measures Cognitive Impairment in COVID-19 Patients

  Jun 15, 2021 — The effects of COVID-19 on the brain can be accurately measured with positron emission tomography (PET), according to research presented at the SNMMI 2021 Annual Meeting. The detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame has been selected as SNMMI’s 2021 Image of the Year.

• Novel Radiotracer Shows Promise to Predict Abdominal Aortic Aneurysm Rupture

  Jun 15, 2021 — A new PET radiotracer can detect abdominal aortic aneurysms and potentially predict when they will rupture, according to research presented at the SNMMI 2021 Annual Meeting.

• SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as President-Elect at 2021 Annual Meeting

  Jun 14, 2021 — Munir Ghesani, MD, FACNM, FACR, has been named as SNMMI president-elect. SNMMI introduced a new slate of officers during its 2021 Virtual Annual Meeting, held June 11-15.

• SNMMI Elects Richard L. Wahl, MD, as President During 2021 Annual Meeting

  Jun 14, 2021 — Richard L. Wahl, MD, has been elected 2021-22 president of the Society of Nuclear Medicine and Molecular Imaging. SNMMI introduced a new slate of officers during its 2021 Virtual Annual Meeting, held June 11-15.

• SNMMI Elects Helen Nadel, MD, FRCPC, as Vice President-Elect at 2021 Annual Meeting

  Jun 14, 2021 — Helen Nadel, MD, FRCPC, has been named as SNMMI vice president-elect. SNMMI introduced a new slate of officers during its 2021 Virtual Annual Meeting, held June 11-15.

• Society of Nuclear Medicine and Molecular Imaging Announces 2021 Fellows

  Jun 14, 2021 — SNMMI recognized 17 new SNMMI Fellows on Monday, June 14, during a plenary session at the society’s 2021 Annual Meeting, held virtually June 11-15.

• Steven M. Larson, MD, Receives SNMMI 2021 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jun 14, 2021 — Steven M. Larson, MD, has been named the 2021 recipient of the prestigious Paul C. Aebersold Award. The award was announced by the SNMMI during its 2021 Annual Meeting.

• New PET Tracer Detects Hallmark of Alzheimer’s Disease Years Before Symptoms Emerge

  Jun 14, 2021 — A novel PET radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed. The research was presented at the SNMMI 2021 Annual Meeting.

• Lipophilic Statin Use Linked to Increased Risk of Dementia

  Jun 14, 2021 — In patients with mild cognitive impairment, taking lipophilic statins more than doubles their risk of developing dementia compared to those who do not take statins. According to research presented at the SNMMI 2021 Annual Meeting, PET scans of lipophilic statin users revealed a highly significant decline in metabolism in the area of the brain that is first impacted by Alzheimer’s disease.

• New Theranostic Approach Combines Radiopharmaceuticals and Nanoparticles to Kill Cancer Cells

  Jun 14, 2021 — Researchers have successfully developed a novel cancer treatment approach that utilizes Cerenkov radiation energy to target and destroy cancer cells more effectively, according to new research presented at SNMMI’s 2021 Virtual Annual Meeting.

• Novel Radiopharmaceutical Tracks “Master Switch” Protein Responsible for Cancer Growth

  Jun 14, 2021 — A protein that is critical in cancer cell metabolism has been imaged for the first time with a newly developed radiopharmaceutical, 18F-DASA-23, according to research presented at the SNMMI 2021 Annual Meeting.

• Deep Learning with SPECT Accurately Predicts Major Adverse Cardiac Events

  Jun 13, 2021 — Deep learning can predict major adverse cardiac events more accurately than current standard imaging protocols, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.

• Thomas J. Ruth, PhD, FRSC, FSRS, Receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award

  Jun 13, 2021 — Thomas J. Ruth, PhD, FRSC, FSRS, a scientist known for his contributions to nuclear medicine and nuclear chemistry, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

• PET Radiotracer Effective for Detection and Assessment of Lung Fibrosis

  Jun 13, 2021 — PET using a Ga-68–labeled fibroblast activation protein inhibitor (FAPI) can noninvasively identify and monitor pulmonary fibrosis, according to research presented at the SNMMI 2021 Annual Meeting.

• New Super-Resolution Technique Allows for More Detailed Brain Imaging

  Jun 13, 2021 — A new imaging technique termed "super-resolution" has the potential to detect neurological disorders—such as Alzheimer’s disease—at their earliest stages, enabling physicians to diagnose and treat patients more quickly.

• Promising Ovarian Cancer Treatment Proves Effective and Efficient

  Jun 12, 2021 — Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass.

• SNMMI Will Engage with CMS to Ensure Coverage of Amyloid PET Imaging

  Jun 9, 2021 — The FDA approved aducanumab on June 7, but amyloid PET scans were not mentioned as a requirement on the drug label. SNMMI will engage with CMS to ensure access and reimbursement for this important diagnostic test.

• FDA Approves New Treatment for Alzheimer’s Disease

  Jun 7, 2021 — The U.S. Food and Drug Administration today approved the human monoclonal antibody Aduhelm (aducanumab) for the treatment of Alzheimer’s disease.

• VISION Trial: Radionuclide Therapy Reduces Death and Disease Progression in Prostate Cancer Patients

  Jun 4, 2021 — The targeted radionuclide therapy 177Lu-PSMA-617 has been proven effective in improving survival in men with advanced prostate cancer, according to recently published results from the VISION trial.

• SNMMI Authors Member Template Letter for SPECT/CT Coverage Denials

  Jun 3, 2021 — After many complaints from our members about SPECT/CT coverage denials from various commercial payers, SNMMI has put forth a resource members can use to contest these decisions.

• DOE Announces New Funding Opportunity

  Jun 2, 2021 — The DOE has announced a new funding opportunity for research to facilitate, streamline, and accelerate the translation of novel radioisotopes and their associated chelating agents and linker/ligands from the laboratory bench to evaluation for potential usage in clinical and pre-clinical trials.

• This Month in JNM

  Jun 1, 2021 — In June JNM: A discussion with Jonathan Allis … Featured: 68Ga-FAPI PET in PDAC … Optoacoustic imaging of GLP-1R … Editorial: Vaccine passports and the law … State of the Art: T.R.U.E. checklist … Hot Topics: ARTnet collaboration … CE: Intro to statistical concepts … Focus on MI: PARP-1 … and more.

• Celebrating Pride Month

  Jun 1, 2021 — SNMMI is proud to recognize and support our LGBTQ+ members with Pride Month celebrations throughout June! At SNMMI, we are committed to celebrating diversity and championing an inclusive, safe, and welcoming environment that respects each member of our professional and patient community. We encourages all nuclear medicine and molecular imaging professionals to actively participate in these efforts.

• FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

  May 27, 2021 — On May 27, the FDA approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. The agent is the first fluorinated PSMA agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

• SNMMI & Partners Urge Congress to Support Medical Research in Infrastructure Legislation

  May 20, 2021 — With legislation under consideration to strengthen the nation’s infrastructure and bolster economic recovery, SNMMI and 228 other medical organizations have urged Congress to include investments in the infrastructure underpinning the medical research enterprise.

• SNMMI Statement: Additional Recommendations: COVID-19 Vaccination and FDG PET/CT

  May 12, 2021 — FDG-avid reactive lymphadenopathy on PET/CT has been reported in patients following COVID-19 vaccinations. SNMMI's COVID-19 Task Force makes additional recommendations based on new information.

• This Month in JNM

  May 11, 2021 — In May JNM: Challenges and Promise for Nuclear Medicine in Africa … State of the Art: PSMA PET for prostate cancer … CE: Evaluation of biomarker cut points … Hot Topics: Tau and cognition … Featured: Imaging therapeutic modulation of PD-L1 … Absolute Tc-99m pyrophosphate quantitation … and more.

• With Advent of New Treatments, PET Imaging Adds Valuable Information to Brain Metastasis Monitoring

  May 3, 2021 — For patients with brain metastases, amino acid PET can provide valuable information about the effectiveness of state-of-the-art treatments.

• Potential Vendors for Amino Acid Solution

  Apr 22, 2021 — SNMMI is aware that many therapy sites for Lu-177 PRRT are experiencing difficulty obtaining compounded amino acid solutions. If your site is affected, this list of compounding pharmacies may be suitable for your institution’s needs.

• Medicare Sequester Moratorium Is Officially Extended

  Apr 15, 2021 — Yesterday, President Biden signed legislation extending the moratorium on Medicare sequestration. This occurred after the House passed the Medicare Sequester Relief Act late Tuesday, which extended mandated 2% Medicare cuts to healthcare providers until the end of the year.

• New Radiotracer Safe and Effective for Imaging Early Rheumatoid Arthritis

  Apr 15, 2021 — New research shows that a novel PET tracer that targets inflammation is safe and can clearly identify early stages of rheumatoid arthritis.

• Now Available and Free to Members! PET/CT in Oncology: Part 2

  Mar 31, 2021 — The SNMMI-TS has just released a new book in the SNMMI-TS Quality and Safety Series: PET/CT in Oncology 2021: Part 2. Members can access the digital versions free of charge or receive a 50% discount on the printed book, now available in the SNMMI Store.

• JNMT: Information to Support Practice during the COVID-19 Pandemic

  Mar 31, 2021 — Don’t miss these important articles in the latest issue of JNMT for essential information designed to help nuclear medicine professionals navigate the current COVID-19 environment!

• SNMMI Statement: The Effect of COVID-19 Vaccination on FDG PET/CT

  Mar 30, 2021 — FDG-avid reactive lymphadenopathy on PET/CT has been reported in patients following COVID-19 vaccinations. SNMMI's COVID-19 Task Force makes recommendations based on the currently available information.

• CMS Confirms HOPPS Payment Rate Error for CERIANNA™ (Fluoroestradiol F-18) Injection

  Feb 22, 2021 — SNMMI has been working with Zionexa to seek proper Medicare reimbursement for Cerianna, radiolabeled 18F-fluoroestradiol indicated for use with positron emission tomography (PET) imaging for detection of estrogen receptor–positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. As of January 2021, the HOPPS published rate for this product is incorrect.

• NRC Unveils Patient Educational Video on Radioactive Drug Therapy

  Jan 26, 2021 — Last week, the U.S. Nuclear Regulatory Commission (NRC) announced the release of the video, “Staying Safe While Getting Better, Protecting Yourself and Your Loved Ones While Taking Radioactive Drugs.”

• SNMMI & Partners Take Action to Ensure Imaging Professionals are Included in Phase 1a of COVID-19 Vaccine Distribution

  Dec 16, 2020 — On December 1, the CDC ACIP recommended that health care personnel who provide direct patient care be the first to receive the COVID-19 vaccination when it becomes available. SNMMI has taken action with partner organizations to support the inclusion of imaging professionals in that allocation.

• New Theranostic Approach Reduces Tumor Volume and Increases Survival in Neuroendocrine Tumor Study

  Dec 15, 2020 — A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival, according to new research published in JNM.

• The Journal of Nuclear Medicine Celebrates 60 Years of Research

  Dec 9, 2020 — The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of leadership in the field of nuclear medicine, molecular imaging and therapy.

• PET Imaging Tracer Proves Effective for Diagnosing and Managing Rare CNS B-Cell Lymphoma

  Dec 9, 2020 — PET imaging with Ga-68-pentixafor is an effective diagnostic tool for central nervous system B-cell lymphoma, according to a proof-of-concept study published in the December issue of JNM.

• FDA Announces First-Ever Approval of PSMA PET for Prostate Cancer Imaging

  Dec 2, 2020 — The FDA has approved ga-68 PSMA-11 for PET imaging of PSMA–positive lesions in men with prostate cancer. It is the first approval for a PSMA PET drug in the United States.

• Multi-Center, Multi-Tracer PET Studies Harmonized to Detect Neuroinflammation in ALS

  Dec 1, 2020 — A novel ALS (amyotrophic lateral sclerosis) study has pooled data from multiple sites to effectively visualize neuroinflammation, which is key to developing drugs to treat the disease.

• This Month in JNM

  Dec 1, 2020 — In December JNM: A Conversation with Frans van Houten, Royal Philips Electronics … State of the Art: 18F-FDG PET recommendations in lung infections … Commentaries: PET/CT in COVID-19, Molecular targeting of COVID-19, Low-dose radiation and COVID-19, Autoimmune encephalitis in COVID-19 … Featured: CXCR4 Imaging of CNS Lymphoma … 67Cu-CuSarTATE for radionuclide therapy … and more.

• Novel Therapy Approach for Hyperinsulinemic Hypoglycemia

  Nov 6, 2020 — A new method to treat hyperinsulinemic hypoglycemia has proved highly selective in targeting lesions and effective in slowing tumor growth, according to research published in the November issue of JNM.

• This Month in JNM

  Nov 2, 2020 — In November JNM: A conversation with David Townsend and Thomas Beyer … State of the art: Improving TRT approaches … CE: Imaging the cancer immune environment … Featured: TSPO radioligand data pooling in ALS … Photodynamic therapy of GLP-1R–positive lesions … Cardiovascular Highlights Lecture … and more.

• SNMMI Joins Other Medical Societies in Support of Osteopathic Physicians

  Oct 29, 2020 — After recent public comments disparaging the legitimacy of osteopathic physicians, SNMMI joined with other medical societies in a statement of support

• SNMMI Joins Medical Societies in Denouncing Claims That Physicians Are Over-Counting COVID-19 Deaths for Financial Gain

  Oct 27, 2020 — SNMMI stands with the Council of Medical Specialty Societies and its fellow medical societies in condemning recent claims that hospitals and physicians are inflating the number of COVID-19 deaths for their own financial gain.

• FDA Approves Cyclotron-Produced Ga-68 DOTATOC for Neuroendocrine Tumors

  Oct 20, 2020 — A new process has been approved for producing gallium-68 (Ga-68) DOTATOC utilizing cyclotron-produced Ga-68, which will allow for higher-volume production.

• DOE Isotope Program Releases Annual Update on Medical Isotopes

  Oct 15, 2020 — The update details the research, development, and production of medically relevant isotopes within the DOE Isotope Program and outlines updates to program initiatives.

• Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug

  Oct 7, 2020 — A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research featured in the October issue of JNM.

• Cerenkov Luminescence Imaging Accurately Identifies Surgical Margin Status During Radical Prostatectomy

  Oct 6, 2020 — A new intraoperative imaging technique, Cerenkov luminescence imaging, can accurately assess surgical margins during radical prostatectomy, according to a first-in-human research published in the October issue of JNM.

• FDA-NRC Workshop: Register Now

  Oct 2, 2020 — Throughout the spring and summer, SNMMI has been working with the Food and Drug Administration (FDA) and Nuclear Regulatory Commission (NRC) on coordinating a workshop to be held on October 14, 2020.

• This Month in JNM

  Oct 1, 2020 — In October JNM: FDA-approved brain tau imaging … AD and neuropathic imaging changes … Featured: Cerenkov luminescence for prostatectomy … Lu-177 lilotomab radioimmunotherapy for NHL … 2020 SNMMI Highlights Lecture—general nuclear medicine … and more.

• NRC Requests Comments on Additional Rulemaking for Extravasations

  Sep 29, 2020 — On September 15th, the U.S. Nuclear Regulatory Commission (NRC) requested comment from the public on whether additional rulemaking is needed to require reporting of certain nuclear medicine injection extravasations as medical events.

• NRC Considering Regulatory Relief for Training for Imaging and Localization Studies

  Sep 19, 2020 — SNMMI along with ASNC, ASTRO and ACR received a response from the NRC regarding their request for regulatory relief for training for imaging and localization studies during the COVID-19 Public Health Emergency.

• SNMMI 2020-2022 Wagner-Torizuka Fellowship Recipients Announced

  Sep 8, 2020 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce the recipients of the 2020-2022 SNMMI Wagner-Torizuka Fellowship.

• Updated Statement: COVID-19 and Ventilation/Perfusion (V/Q) Lung Studies

  Sep 3, 2020 — SNMMI has released an updated statement on COVID-19 and ventilation/perfusion (V/Q) lung studies.

• Virtual Patient Education Day Event Draws 600+ Viewers

  Aug 28, 2020 — SNMMI and its Patient Advocacy Advisory Board (PAAB) held the Society’s annual Patient Education Day this year as a series of three virtual sessions, reaching the highest number of patients in the event’s nine-year history.

• A Virtual Celebration of Life for Sam Gambhir, MD, PhD to take place on Friday, August 14, 2020

  Aug 8, 2020 — A Virtual Celebration of Life will take place on Friday, August 14, 2020 to honor molecular imaging pioneer Sanjiv “Sam” Gambhir, MD, PhD, who passed away on Saturday, July 18, from cancer.

• This Month in JNM

  Aug 3, 2020 — In August JNM: Discussions with Christoph Zindel and Kelsey Martin … COVID: PRRT during COVID-19 ; Overcoming the COVID-19 crisis … Hot Topics: Workforce impact of COVID-19 ; Amyloid and tau PET for drug testing … Focus on MI: PET and neuroinflammation … State of the Art: Molecular image-guided surgery … Featured: PET/MRI versus PET/CT in oncology … Targeted radionuclide therapy for TNBC … Special Contribution: AUC for PET MPI

• Molecular Imaging Pioneer Sam Gambhir Passes Away

  Jul 19, 2020 — Molecular imaging pioneer Sanjiv “Sam” Gambhir, MD, PhD, passed away on Saturday, July 18, from cancer.

• SNMMI Announces Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, as President of Technologist Section during 2020 Annual Meeting

  Jul 14, 2020 — Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, has been named 2020-21 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section.

• SNMMI Announces Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT) as President-Elect of the Technologist Section During 2020 Annual Meeting

  Jul 14, 2020 — Dusty M. York, MAEd, CNMT, PET, ARRT(N)(CT), has been elected as the 2020-21 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section.

• SNMMI Elects Richard L. Wahl, MD, as President-Elect During 2020 Annual Meeting

  Jul 13, 2020 — Richard L. Wahl, MD, has been elected 2020-21 president-elect of the Society of Nuclear Medicine and Molecular Imaging.

• SNMMI Elects Alan B. Packard, PhD, as President During 2020 Annual Meeting

  Jul 13, 2020 — Alan Packard, PhD, has been elected 2020-21 president of the Society of Nuclear Medicine and Molecular Imaging.

• Society of Nuclear Medicine and Molecular Imaging Announces 2020 Fellows

  Jul 13, 2020 — The Society of Nuclear Medicine and Molecular Imaging recognized 10 new SNMMI Fellows on Monday, July 13, during a plenary session at the society’s 2020 Annual Meeting.

• SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as Vice President-Elect During 2020 Annual Meeting

  Jul 13, 2020 — Munir Ghesani, MD, FACNM, FACR, has been named as vice president-elect for the Society of Nuclear Medicine and Molecular Imaging.

• Novel Bone Imaging Approach Provides Insights into the Progression of Knee Osteoarthritis

  Jul 12, 2020 — A new approach to functional bone imaging has established that bone metabolism is abnormally elevated in patients with knee osteoarthritis.

• Total-Body Dynamic PET Successfully Detects Metastatic Cancer; First Patient Results Reported

  Jul 12, 2020 — Results from the first study using uEXPLORER to conduct total-body dynamic positron emission tomography (PET) scans in cancer patients show that it can be used to generate high-quality images of metastatic cancer.

• In Recurrent Prostate Cancer, PSMA PET/CT Changes Management in Two-Thirds of Cases

  Jul 12, 2020 — New research confirms the high impact of PSMA PET/CT in the detection and management of recurrent disease in prostate cancer patients.

• Molecular Imaging Identifies Link between Heart and Kidney Inflammation after Heart Attack

  Jul 12, 2020 — Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction, or heart attack.

• Carolyn J. Anderson, PhD, Receives SNMMI 2020 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jul 12, 2020 — Carolyn J. Anderson, PhD, has been named the 2020 recipient of the prestigious Paul C. Aebersold Award. Anderson is a professor in the departments of medicine, radiology, bioengineering, chemistry, and pharmacology and chemical biology at the University of Pittsburgh in Pennsylvania.

• Stephen L. Bacharach, PhD, Receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award

  Jul 12, 2020 — Stephen L. Bacharach, PhD, a physicist known for his research in cardiac and PET oncology imaging, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

• New PET Radiotracer Proven Safe and Effective in Imaging Malignant Brain Tumors

  Jul 12, 2020 — A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived PET tracer, in patients with glioblastomas.

• New PET/MRI Approach Pinpoints Chronic Pain Location, Alters Management

  Jul 11, 2020 — A new molecular imaging approach utilizing 18F-FDG positron emission tomography (PET) and magnetic resonance imaging can precisely identify the location of pain generators in chronic pain sufferers, often precipitating a new management plan for patients.

• Total-Body PET/CT Captures Full Picture of Systemic Inflammatory Arthritis

  Jul 11, 2020 — For the first time, physicians can examine the systemic burden of inflammatory arthritis simultaneously across all joints and organ systems, using the high-sensitivity, high-resolution uEXPLORER total-body positron emission tomography/computed tomography scanner

• Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies

  Jul 11, 2020 — Targeted radionuclide therapy has been found to create a favorable tumor microenvironment in prostate cancer that improves the effectiveness of immunotherapies.

• Novel Radiotracer Measures Synaptic Activity After Stroke

  Jul 11, 2020 — A new radiotracer, 18F-SynVesT-2, can directly assess synaptic density changes in the brain, providing an objective and quantitative measure of disease progression after stroke.

• New Theranostic Agents Demonstrate Efficacy in Treatment of Prostate Cancer in Preclinical Studies

  Jul 11, 2020 — Researchers have developed a new pair of agents that show exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies.

• SNMMI Hosts FDA Townhall on the Impact of COVID-19

  Jul 10, 2020 — On Wednesday, June 17th, SNMMI hosted an FDA Townhall on the Impact of COVID-19 on regulatory activities.

• This Month in JNM

  Jul 2, 2020 — In July JNM: Editorial: Unacceptable Denials … Thomas Beyer interviews Yasuhito Sasaki … Featured: 212Pb-anti-CD38 in multiple myeloma … Single-time-point 177Lu-PSMA dosimetry … State of the Art: Toward molecular nuclear cardiology … Hot Topics: ISCHEMIA trial … and more.

• Journal of Nuclear Medicine Impact Factor Jumps More than Seven Percent

  Jun 29, 2020 — The Journal of Nuclear Medicine has achieved the highest impact factor ever in its 6o-year history, ranking fourth among all medical journals worldwide, according to new data just released in the 2019 Journal Citation Reports published by Clarivate Analytics.

• SNMMI Requests Regulatory Relief for Training for Imaging and Localization Studies

  Jun 11, 2020 — Today, SNMMI along with ASNC, ASTRO and ACR requested regulatory relief for Training for imaging and localization studies during the COVID-19 Public Health Emergency.

• This Month in JNM

  Jun 4, 2020 — In June JNM: A Conversation Between Johnese Spisso and Johannes Czernin … A Conversation Between Howard Soule and Johannes Czernin … COVID articles and commentaries … Guidance and best practices for nuclear cardiology laboratories during the COVID-19 pandemic … Featured: 68Ga-DOTA-JR11 in NETs … Glucose transport in neuroendocrine prostate cancer … and more.

• SNMMI Statement on Racism in Healthcare

  Jun 2, 2020 — SNMMI stands in unity with the Council of Medicine Specialty Societies (CMSS) and the 800,000 physicians across 45 medical specialties that deplore the negative impact of racism in our nation and of racial inequities in our healthcare system

• USP Announces New Implementation Date for USP General Chapter <825>

  Jun 1, 2020 — The United States Pharmacopeial Convention (USP) has updated the implementation date for General Chapter <825> Radiopharmaceuticals – Preparation, Compounding, Dispensing, and Repackaging to December 1, 2020.

• Recent HHS Updates During the COVID-19 Pandemic

  May 19, 2020 — As we wait the enactment of a fourth stimulus package, SNMMI would like to inform its membership of the recent U.S. Department of Health and Human Services (HHS) administrative updates as a result of COVID-19.

• SNMMI Advocates for Access to Diagnostic Radiopharmaceuticals through COVID-19 and Beyond

  May 15, 2020 — This week SNMMI and its coalition partners sent a letter imploring Congress to take immediate action to ensure patient access to FDA-approved diagnostic radiopharmaceutical drugs that aid in the detection of cancer, cardiovascular conditions and neurological disorders.

• SNMMI Advocates for Frontline Healthcare Workers

  May 8, 2020 — SNMMI joined various other medical professional societies in advocating for all frontline members of the healthcare delivery system during the COVID-19 pandemic

• SNMMI and Peer Societies Issue Guide to Safe Reintroduction of Cardiovascular Services

  May 5, 2020 — Fifteen major cardiovascular societies in North America, including SNMMI, have come together to outline a systematic approach to reinstating diagnostic and therapeutic cardiovascular services during the COVID-19 pandemic.

• Technologists Answer Questions about COVID-19

  May 5, 2020 — The COVID-19 crisis has forced nuclear medicine departments to cancel appointments, change procedures and protocols and adapt rapidly to significant changes. To provide guidance to the community, SNMMI-TS interviewed eight nuclear medicine technologists from around the country.

• This Month in JNM

  May 3, 2020 — In May JNM: COVID-19 commentaries … New JNM Feature: The Standard of Care—From Nuclear Radiology to Nuclear Medicine … A Discussion Between Ignasi Carrió and Ken Herrmann … Novel tracers in immunotherapy … Genotype and PPGL imaging … Analyzing paraganglioma imaging … Featured: PSMA-TAT and mutated DNA repair genes … Imaging ?H2AX after Lu-177-DOTATATE … and more.

• Public Meeting to Discuss 10 CFR Part 37 Regulatory Relief Pathways for NRC Licensees

  May 1, 2020 — On Tuesday, May 5, at 1:00 p.m. EDT, the NRC will be holding a public meeting to discuss potential regulatory relief pathways for NRC 10 CFR Part 37 licensees during the COVID-19 public health emergency.

• Announcement: SNMMI Annual Meeting

  Apr 30, 2020 — SNMMI President Vasken Dilsizian, MD, shares an important message unveiling the re-imagined SNMMI 2020 Annual Meeting—Virtual Edition.

• CARES ACT 2.0: HHS Gets Another Infusion of $100 Billion

  Apr 24, 2020 — $75 billion is allocated for reimbursement to hospitals and healthcare providers to support the need for COVID-19 related expenses and lost revenue. The language remains the same as CARES Act. $25 billion is designated for necessary expenses to research, develop, validate, manufacture, purchase, administer, and expand capacity for COVID-19 tests.

• SNMMI Receives Good News from KLM regarding Radioisotope Supply

  Apr 20, 2020 — Based on humanitarian needs and medical urgency, KLM has agreed to resume the transport of medical isotopes from Europe to the United States beginning April 27th.

• Congressman Greg Murphy, MD, Signs On to the Medicare Diagnostic Radiopharmaceutical Payment Equity Act

  Apr 16, 2020 — Last week, SNMMI had the chance to sit down and talk with Congressman Greg Murphy, MD, a urologist representing North Carolina’s 3rd Congressional district. Congressman Murphy is the first physician to sign on to HR 3772, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act.

• Update: SNMMI Annual Meeting

  Apr 13, 2020 — SNMMI is receiving many inquiries about the status of the upcoming Annual Meeting, planned for June 13-16 in New Orleans. SNMMI leadership is watching very closely as the situation progresses—in New Orleans, in the United States and worldwide.

• SNMMI Expands Virtual Curriculum — Available to All Members at No Charge

  Apr 10, 2020 — As we reach the peak of the COVID crisis, many of us are pausing to catch our breath and look ahead to the “new normal” of our lives for the next few months. Education is a high priority, and SNMMI is here to support you with free, flexible access to SNMMI’s extensive virtual curriculum.

• The NMEu Meets to Discuss COVID-19 and the Global Supply of Mo-99

  Apr 8, 2020 — On Monday, April 6th the Nuclear Medicine Europe (NMEu’s) Security of Supply Working Group (SoS WG) Emergency Response Team (ERT) held a teleconference to discuss the impact of the COVID-19 pandemic on Mo-99 and other radioisotope production.

• This Month in JNM

  Apr 6, 2020 — In April JNM:A discussion with John Sunderland … Patient travel concerns after Lu-177-DOTATATE … The academic NDA … AUC for biochemical recurrence of prostate cancer … Featured: F-18 versus Ga-68-PSMA imaging … and more.

• SNMMI Announces COVID-19 Resource Center

  Mar 27, 2020 — As COVID-19 escalates all over the world, we all are facing serious new challenges. SNMMI has developed a COVID-19 Resource Center to consolidate information and resources for the nuclear medicine community.

• SNMMI Encourages Legislators To Ensure Accessibility to PPE

  Mar 26, 2020 — On Thursday, March 26, the Society of Nuclear Medicine and Molecular Imaging joined the American College of Radiology, the American Society of Radiologic Technologists, the American Registry of Radiologic Technologists, the Nuclear Medicine Technologist Certification Board and the Society of Diagnostic Medical Sonography in calling for an adequate supply of personal protective equipment (PPE).

• Celebrating Women in Medicine Month

  Sep 5, 2019 — September 5 is Women in Medicine Day and SNMMI is excited to join the American Medical Association (AMA) in celebrating Women in Medicine Month throughout September! We will be honoring this year’s theme, “Women in Medicine: Trailblazers, Advocates, Leaders,” all month long, recognizing the achievements, contributions, and trailblazing efforts of women in our nuclear medicine and molecular imaging community.

• Fall Education Preview

  Aug 28, 2019 — We know you're busy. That's why you need on-demand access to industry news, research, and education available at your fingertips. SNMMI offers a wide variety of programs that provide relevant and timely educational content for nuclear medicine and molecular imaging professionals at every stage in their career. See the SNMMI Education Fall Preview below and register now for the professional development events best suited to your needs.

• Ones to Watch – Early Career Professionals Making a Difference in 2019

  Mar 18, 2019 — We are proud to present this selection of 30 rising stars in nuclear medicine and molecular imaging. With help from the Committee on Councils and Centers and the SNMMI-TS Professional Development Task Force, SNMMI has identified these young professionals as “Ones to Watch” in 2019. The future looks bright!

• This Month in JNM

  Feb 1, 2019 — The February 2019 issue of The Journal of Nuclear Medicine is now available. Discussions with Leaders: A Conversation between Steven Larson and Johannes Czernin. Hot Topic: Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer. Featured: 18F-GP1 PET for thromboembolism; 18F-FFNP uptake with estradiol challenge in breast cancer ... and more.

• This Month in JNM

  Jan 2, 2019 — The January 2019 issue of The Journal of Nuclear Medicine is now available. Read about VT substrate characteristics,18F-flortanidazole PET in treated NSCLC, 18F-P3BZA PET/CT in melanoma, and more. Also, check out the second in the "Discussions with Leaders" series: a conversation with Richard Wahl.

• This Month in JNM

  Dec 3, 2018 — The December 2018 issue of The Journal of Nuclear Medicine is now available. Read about three novel tau radiopharmaceuticals for imaging patients with amyloid-positive Alzheimer disease, whole-body 68Ga-PSMA-11 PET/MR, immuno-PET after BACE-1 inhibition, and more. Also, check out the first in a new series of articles: "Discussions with Leaders."

• This Month in JNM

  Nov 1, 2018 — The November 2018 issue of The Journal of Nuclear Medicine is now available. Read about c-Met-targeted imaging of non-small cell lung cancer, Ga-68-PSMA-11 PET/CT for radiation treatment planning, the current state of radiopharmaceutical therapy, and more.

• This Month in JNM

  Oct 1, 2018 — The October 2018 issue of The Journal of Nuclear Medicine is now available. Read about PET imaging for nicotinic acetylcholine receptors, imaging liver lymphocytes and more!

• USP Plans to Establish New Chapter for Radiopharmaceuticals and Calls for Candidates on Expert Panel

  Jun 2, 2017 — The USP plans to establish a new General Chapter <825> Compounding-Radiopharmaceuticals.

• 2017 Robert E. Henkin Government Relations Fellowship

  May 31, 2017 — The fellows spent a week in Washington, DC, and gained firsthand knowledge of Capitol Hill and inside federal agencies.

• FDA Issues Draft Guidances on Compounding and Repackaging Radiopharmaceuticals

  Jan 11, 2017 — The FDA issued two draft guidances that describe FDA’s proposed policies regarding the compounding and repackaging of radiopharmaceuticals for human use by state-licensed nuclear pharmacies or federal facilities, and outsourcing facilities.

• SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals

  Dec 14, 2016 — SNMMI has developed USP Recommendations for Compounded Sterile Radiopharmaceuticals.